These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1981143)
1. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143 [TBL] [Abstract][Full Text] [Related]
2. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. Ethier SP; Kokeny KE; Ridings JW; Dilts CA Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031 [TBL] [Abstract][Full Text] [Related]
3. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. Corbett IP; Henry JA; Angus B; Watchorn CJ; Wilkinson L; Hennessy C; Gullick WJ; Tuzi NL; May FE; Westley BR J Pathol; 1990 May; 161(1):15-25. PubMed ID: 1973458 [TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2. Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535 [TBL] [Abstract][Full Text] [Related]
6. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Yu D; Wolf JK; Scanlon M; Price JE; Hung MC Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034 [TBL] [Abstract][Full Text] [Related]
7. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Maier LA; Xu FJ; Hester S; Boyer CM; McKenzie S; Bruskin AM; Argon Y; Bast RC Cancer Res; 1991 Oct; 51(19):5361-9. PubMed ID: 1680547 [TBL] [Abstract][Full Text] [Related]
8. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells. Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001 [TBL] [Abstract][Full Text] [Related]
9. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation. Meenakshi A; Kumar RS; Kumar NS Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421 [TBL] [Abstract][Full Text] [Related]
10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231 [TBL] [Abstract][Full Text] [Related]
11. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha. Kumar R; Mendelsohn J Anticancer Res; 1994; 14(3A):1001-8. PubMed ID: 7915505 [TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Lee H; Maihle NJ Oncogene; 1998 Jun; 16(25):3243-52. PubMed ID: 9681822 [TBL] [Abstract][Full Text] [Related]
13. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187 [TBL] [Abstract][Full Text] [Related]
14. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407 [TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Ram TG; Ethier SP Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665 [TBL] [Abstract][Full Text] [Related]
16. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637 [TBL] [Abstract][Full Text] [Related]